T1	Participants 224 263	62 patients with advanced breast cancer
T2	Participants 741 775	Patients in the CEF + GM-CSF group
T3	Participants 473 739	Patients received CEF (cyclophosphamide 600 mg m-2, epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2) i.v. on day 1 or the same chemotherapy, plus GM-CSF 10 micrograms kg-1 s.c. starting from day 4, repeated as soon as haematopoietic recovery from nadir occurred
